# US 2016/0354442 A1 · Therapeutic method of inducing mitochondrial biogenesis to treat skin and muscle pathologies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354442 A1
- Document ID: US20160354442A1
- Status: Published application
- Kind: A1
- Application number: 14/992,969
- Filed: 2016-01-11
- Published: 2016-12-08
- Earliest claimed: 2013-07-11
- Assignees: Exerkine Corporation
- Applicants: Exerkine Corporation
- Inventors: Mark Tarnopolsky; Justin Crane
- Web page: https://patentgrep.com/patent/US20160354442A1

## CPC

- A61K 38/2086: {IL-13 to IL-16}
- A61K 8/606: {Nucleosides; Nucleotides; Nucleic acids}
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/10: Sulfides; Sulfoxides; Sulfones
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61Q 19/08: Anti-ageing preparations
- C07K 14/5443: {IL-15}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method of inducing mitochondrial biogenesis in a mammal is provided. The method comprises the step of administering to the mammal an interleukin-15 or nucleic acid encoding an interleukin-15 to the mammal.

## Claims

### Claim 1

A method of inducing mitochondrial biogenesis in a mammal comprising the step of administering to the mammal interleukin-15, or nucleic acid encoding interleukin-15.

### Claim 2 (depends on 1)

The method of claim 1, wherein the interleukin-15 is selected from human interleukin-15 and functionally equivalent variants thereof which exhibit at least about 70% sequence homology thereto.

### Claim 3 (depends on 1)

The method of claim 1, wherein the interleukin-15-encoding nucleic acid is selected from human interleukin-15-encoding nucleic acid and functionally equivalent variants thereof which encode a functionally equivalent variant of interleukin-15 that exhibits at least about 70% sequence homology thereto.

### Claim 4 (depends on 1)

The method of claim 1, wherein interleukin-15 is administered as a dosage in the range of about 0.1 pg/kg to 50 ng/kg, or interleukin-15-encoding nucleic acid is administered in an amount that yields a dosage of about 0.1 pg/kg to 50 ng/kg interleukin-15.

### Claim 5 (depends on 1)

The method of claim 1, wherein interleukin-15 is administered in a dosage sufficient to increase plasma levels of interleukin-15 by between about 0.1-60 pg/ml, or to increase plasma levels of interleukin-15 to no more than about 100 pg/ml.

### Claim 6 (depends on 1)

The method of claim 1, wherein the interleukin-15 or interleukin-15-encoding nucleic acid is administered orally, subcutaneously, intravenously, intraperitoneally, intranasally, enterally, topically, sublingually, intramuscularly, intra-arterially, intramedullarily, intrathecally, ocularly, transdermally, vaginally, rectally or by inhalation.

### Claim 7 (depends on 1)

The method of claim 1, wherein the interleukin-15 or interleukin-15-encoding nucleic acid is administered in conjunction with a second therapeutic agent.

### Claim 8 (depends on 7)

The method of claim 7, wherein the second therapeutic agent is an agent useful to induce mitochondrial biogenesis.

### Claim 10 (depends on 7)

The method of claim 7, wherein the second therapeutic agent is effective to treat a skin pathology and is selected from the group of: corticosteroid cream or ointment, a systemic corticosteroid, DMSO, coenzyme Q10, alpha lipoic acid, vitamin C, vitamin E, an immune modulator or immunosuppressor, an antibiotic, an antihistamine, a sunscreen, an emollient and phototherapy.

### Claim 11 (depends on 1)

The method of claim 1, for the treatment of a skin pathology.

### Claim 12 (depends on 11)

The method of claim 11, wherein the skin pathology is selected from the group consisting of photoaging, actinic keratosis, carcinoma, pre-cancerous lesions, vascular disorders, skin injuries, autoimmune skin disorders, intrinsic skin aging and extrinsic skin aging.

### Claim 13 (depends on 11)

The method of claim 11, wherein the interleukin-15 or nucleic acid encoding interleukin-15 is formulated for topical administration.

### Claim 14 (depends on 1)

The method of claim 1, for the treatment of a muscle pathology.

### Claim 15 (depends on 14)

The method of claim 14, wherein the muscle pathology is selected from the group consisting of immune-mediated myopathies, primary mitochondrial genetic disorders, aging-associated muscle pathologies and muscle dystrophies.

### Claim 16 (depends on 15)

The method of claim 15, wherein the primary mitochondrial genetic disorder is selected from the group consisting of MELAS, MERRF, LHON, POLG1 mutations and CPEO, the muscle dystrophy is selected from the group consisting of Duchenne, Becker, limb-girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal and Emery-Dreifuss muscular dystrophy, and immune-mediated myopathies are selected from the group consisting of polymyositis, dermatomyosistis and inclusion body myopathy.

### Claim 17

A composition useful to induce mitochondrial biogenesis in a mammal comprising interleukin-15 or nucleic acid encoding interleukin-15 in combination with a pharmaceutically acceptable carrier to yield a topically administrable formulation.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the formulation is a cream, lotion, ointment, emollient or sunscreen formulation.

### Claim 19 (depends on 17)

The composition as defined in claim 17, comprising a second therapeutic agent which induces mitochondrial biogenesis.

### Claim 20 (depends on 17)

The composition of claim 17, comprising a second therapeutic agent that is effective to treat a skin pathology and is selected from the group of: corticosteroid cream or ointment, a systemic corticosteroid, DMSO, coenzyme Q10, alpha lipoic acid, vitamin C, vitamin E, an immune modulator or immunosuppressor, an antibiotic, an antihistamine, a sunscreen and an emollient.
